Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis

Conclusions: Certolizumab pegol may successfully treat RAassociated scleritis, even in a patient who has not tolerated therapy with other tumor necrosis factor alpha antagonists or in whom that treatment has failed.

Results: Six months after beginning the new therapy, it was welltolerated and the patient's RA and scleritis were quiescent.

Purpose: To report the successful treatment of rheumatoid arthritis (RA)-associated scleritis with the tumor necrosis factor alpha antagonist certolizumab pegol.

Methods: Retrospective case report of therapeutic interventions for a 47-year-old woman with scleritis and RA. After not tolerating treatment with other tumor necrosis factor alpha inhibitors and rituximab, or after that treatment failed, certolizumab pegol was administered in an attempt to achieve better control of her disease process.